CARDINAL HEALTH INC CAH
Last close
247.18
2026-09-04
Market cap
$57.49B
2026-06-30 share count
52-week range
145.87 - 258.30
Valuation FY2026 figures against the last close
P/S0.2x
P/E34.2x
P/FCF12.7x
EV/EBITDA16.1x
Dividend yield0.9%
Diluted EPS7.23
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B |
| Cost of revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B | $123.43B |
| Gross profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B |
| SG&A | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B | $3.77B |
| Operating income | $2.61B | $2.27B | $1.24B | $752.0M | -$607.0M | $472.0M | -$4.10B | $2.06B | $126.0M | $2.12B |
| Interest expense | $348.0M | $215.0M | $51.0M | $84.0M | $147.0M | $180.0M | $238.0M | $294.0M | $329.0M | $201.0M |
| Pre-tax income | $2.17B | $2.10B | $1.20B | $663.0M | -$784.0M | $323.0M | -$3.77B | $1.75B | -$228.0M | $1.92B |
| Income tax | $469.0M | $532.0M | $348.0M | $332.0M | $153.0M | $289.0M | $79.0M | $386.0M | $487.0M | $630.0M |
| Net income | $1.71B | $1.56B | $852.0M | $330.0M | -$938.0M | $611.0M | -$3.70B | $1.36B | $256.0M | $1.29B |
| EPS, basic | 7.27 | 6.48 | 3.48 | 1.27 | -3.37 | 2.09 | -12.61 | 4.55 | 0.82 | 4.06 |
| EPS, diluted | 7.23 | 6.45 | 3.45 | 1.26 | -3.37 | 2.08 | -12.61 | 4.53 | 0.81 | 4.03 |
| Shares, diluted (wtd. avg.) | $237.0M | $242.0M | $247.0M | $262.0M | $279.0M | $294.0M | $293.0M | $301.0M | $315.0M | $320.0M |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.75B | $3.38B | $2.77B | $2.53B | $1.76B | $6.88B |
| Short-term investments | — | — | $200.0M | — | — | — | — | — | — | — |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B | $9.10B | $8.26B | $8.45B | $7.80B | $8.05B |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B | $14.59B | $13.20B | $12.82B | $12.31B | $11.30B |
| Total current assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B | $31.05B | $25.94B | $25.75B | $24.55B | $28.34B |
| Property, plant and equipment | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B | $2.36B | $2.37B | $2.36B | $2.49B | $1.88B |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B | $7.99B | $8.36B | $8.38B | $8.32B | $7.22B |
| Other intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B | $2.10B | $2.92B | $3.43B | $3.91B | $1.99B |
| Total assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B |
| Accounts payable | $38.28B | $34.71B | $31.76B | $29.93B | $27.13B | $23.70B | $21.37B | $21.54B | $19.68B | $17.91B |
| Total current liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B | $27.62B | $23.61B | $24.11B | $22.89B | $21.22B |
| Retained earnings | $2.01B | $783.0M | -$286.0M | -$642.0M | -$280.0M | $1.21B | $1.17B | $5.43B | $4.64B | $4.97B |
| Total equity | -$2.88B | -$2.78B | -$3.21B | -$2.96B | -$882.0M | $1.62B | $1.79B | $6.33B | $6.06B | $6.83B |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B | $2.43B | $1.96B | $2.72B | $2.77B | $1.18B |
| Depreciation and amortisation | $956.0M | $790.0M | $710.0M | $692.0M | $692.0M | $783.0M | $913.0M | $1.00B | $1.03B | $717.0M |
| Stock-based compensation | $367.0M | $244.0M | $121.0M | $96.0M | $81.0M | $89.0M | $90.0M | $82.0M | $85.0M | $96.0M |
| Capital expenditure | $649.0M | $547.0M | $511.0M | $481.0M | $387.0M | $400.0M | $375.0M | $328.0M | $384.0M | $387.0M |
| Investing cash flow | -$2.58B | -$5.59B | -$1.85B | -$454.0M | $567.0M | -$378.0M | $493.0M | $338.0M | -$5.61B | -$405.0M |
| Financing cash flow | -$1.60B | $1.94B | -$847.0M | -$3.05B | -$2.46B | -$1.32B | -$2.20B | -$2.29B | -$2.28B | $3.75B |
| Dividends paid | $491.0M | $494.0M | $499.0M | $525.0M | $559.0M | $573.0M | $569.0M | $577.0M | $581.0M | $577.0M |
| Buybacks | $1.36B | $765.0M | $750.0M | $2.00B | $1.00B | $200.0M | $350.0M | $600.0M | $550.0M | $600.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000721371-26-000038.
Others in SIC 5122
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MCK | MCKESSON CORP | $105.86B | 23.7x | 12.4% |
| COR | Cencora, Inc. | $63.15B | 41.6x | 9.3% |
| HLF | HERBALIFE LTD. | $1.30B | 5.6x | 0.9% |
| NUS | NU SKIN ENTERPRISES, INC. | $235.6M | 1.5x | -14.3% |
| COSM | Cosmos Health Inc. | $27.5M | — | 19.9% |
| HWH | HWH International Inc. | $14.5M | — | -30.8% |
| MEDS | DataMeds AI, Inc. | $2.8M | — | 28.7% |
| HKPD | Cellyan Biotechnology Co., Ltd | — | — | — |